FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - October 10, 2025 388 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify patients with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR... May 28, 2021 EMA Recommends Extension of Therapeutic Indications for Epcoritamab July 24, 2026 Patient Guide on Immunotherapy Side Effects and Their Management Now Available... November 26, 2025 What Happens If More People Get Screened for Cancer? January 26, 2024 Load more HOT NEWS The ecDNA story – catching the mastermind behind cancer evolution 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with... Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years... The Appraisal – Scientific disruption: what is it, and do we...
